Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Sales expansion to new customers, steady shipment volumes of medical oxygen and carbon dioxide, product price revisions and expense efficiency measures, steady performance of HOT and CPAP, streamlining measures, completion of large-scale projects, sales activities, greater awareness and staff increases, among other factors
None applicable
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥7,839 million (YoY +6.3%) |
| Operating profit | ¥958 million (YoY +11.0%) |
| Ordinary income | ¥1,013 million (YoY +10.5%) |
| Profit attributable to owners of the parent | ¥675 million (YoY +8.5%) |
| Net income per share | ¥216.12 |
| Equity ratio | End of the current fiscal period 76.0% / End of previous period 74.8% |
| Total assets | ¥26,931 million |
| Net assets | ¥20,790 million |
| Cash flows from operating activities | ¥816 million |
| Cash flows from investing activities | ¥-795 million |
| Cash flows from financing activities | ¥-546 million |
| Cash and cash equivalents at end of period | ¥5,385 million |
| Full-year earnings forecast | Net Sales ¥15,660 million (YoY +0.9%) / Operating profit ¥1,980 million (YoY +3.2%) / Ordinary income ¥2,060 million (YoY +3.0%) / Profit attributable to owners of the parent ¥1,400 million (YoY +2.0%) |
| Revision to Earnings Forecast | No revision |
| Annual Dividend Forecast | ¥90.00 → ¥100.00（11.1%） |
| Segment revenue | Medical Gas Business ¥1,985 million (YoY +2.5%), Home Healthcare Business ¥3,833 million (YoY +7.9%), Medical Gas Equipment Construction Business ¥666 million (YoY +8.6%), Nursing Care and Welfare Business ¥661 million (YoY +13.6%), Residential Care Business ¥171 million (YoY -2.6%), Other ¥520 million |
| Segment profit | Medical Gas Business ¥300 million (YoY +6.4%), Home Healthcare Business ¥472 million (YoY +9.5%), Medical Gas Equipment Construction Business ¥103 million (YoY +12.7%), Nursing Care and Welfare Business ¥14 million, Residential Care Business ¥-9 million, Other ¥77 million |
| Depreciation and amortization | ¥528 million |
| Impairment loss | None recorded (no applicable information regarding impairment losses on property, plant and equipment by reporting segment) |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Not recorded |
| Disclosure regarding the going concern assumption | None applicable |
| Change in accounting policy | Changes due to revisions to standards None / Other changes None / Change in accounting estimate None / Restatement None |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies |
| Availability of Supplementary Financial Results Materials | Available |
| Availability of Financial Results Briefing | Whether applicable None / Subject person Not disclosed |
| Issued Shares at Period-End | 3,420,000 shares |
| Treasury Shares at Period-End | 295,110 shares |
| Factors Behind Changes in Business Performance | Sales expansion to new customers, steady shipment volumes of medical oxygen and carbon dioxide, product price revisions and expense efficiency measures, steady performance of HOT and CPAP, streamlining measures, completion of large-scale projects, sales activities, greater awareness and staff increases, among other factors |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the medical gas-related business, sales expansion to new customers, steady shipment volumes, product price revisions and expense efficiency measures progressed. In the home healthcare-related business, HOT and CPAP performed steadily, and streamlining measures were advanced. In the medical gas equipment construction-related business, multiple large-scale projects were completed, while the nursing care and welfare-related business pursued sales activities, greater awareness and staff increases.